Dr. Alexander J. Chou
Claim this profileNYP/Weill Cornell Medical Center
Expert in Cancer
Expert in Non-Hodgkin's Lymphoma
17 reported clinical trials
39 drugs studied
About Alexander J. Chou
Education:
- Graduated from Weill Cornell Medical College, Cornell University, Class of 1998.
- Completed Residency in Pediatrics at New York Presbyterian Hospital (Cornell Campus), 1998-2001.
- Undertook Fellowship in Pediatric Hematology/Oncology at New York Presbyterian Hospital (Cornell Campus), 2002-2005.
Experience:
- Served as Assistant Professor of Pediatrics at Weill Cornell Medicine and Assistant Attending Pediatrician at NewYork-Presbyterian/Weill Cornell Medical Center.
- Held the position of Clinical Director of Pediatric Sarcoma Service at the Children's Hospital at Montefiore and was a Member of the Pediatric Sarcoma Service at Memorial Sloan Kettering Cancer Center.
- Has over 20 years of experience, focusing on pediatric sarcomas and solid tumors, with significant contributions to research and clinical trials in his field.
Area of expertise
1Cancer
Global LeaderStage IV
FOXO1 fusion negative
FOXO1 fusion positive
2Non-Hodgkin's Lymphoma
Global LeaderStage IV
Stage I
Stage II
Affiliated Hospitals
Clinical Trials Alexander J. Chou is currently running
CPX-351 + Gilteritinib
for Acute Myeloid Leukemia
This phase III trial compares standard chemotherapy to therapy with liposome-encapsulated daunorubicin-cytarabine (CPX-351) and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3 mutations. Drugs used in chemotherapy, such as daunorubicin, cytarabine, and gemtuzumab ozogamicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. CPX-351 is made up of daunorubicin and cytarabine and is made in a way that makes the drugs stay in the bone marrow longer and could be less likely to cause heart problems than traditional anthracycline drugs, a common class of chemotherapy drug. Some acute myeloid leukemia patients have an abnormality in the structure of a gene called FLT3. Genes are pieces of DNA (molecules that carry instructions for development, functioning, growth and reproduction) inside each cell that tell the cell what to do and when to grow and divide. FLT3 plays an important role in the normal making of blood cells. This gene can have permanent changes that cause it to function abnormally by making cancer cells grow. Gilteritinib may block the abnormal function of the FLT3 gene that makes cancer cells grow. The overall goals of this study are, 1) to compare the effects, good and/or bad, of CPX-351 with daunorubicin and cytarabine on people with newly diagnosed AML to find out which is better, 2) to study the effects, good and/or bad, of adding gilteritinib to AML therapy for patients with high amounts of FLT3/ITD or other FLT3 mutations and 3) to study changes in heart function during and after treatment for AML. Giving CPX-351 and/or gilteritinib with standard chemotherapy may work better in treating patients with acute myeloid leukemia compared to standard chemotherapy alone.
Recruiting2 awards Phase 3
Health Information Collection
for Childhood Cancer
This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care.
Recruiting1 award N/A10 criteria
More about Alexander J. Chou
Clinical Trial Related8 years of experience running clinical trials · Led 17 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Alexander J. Chou has experience with
- Selpercatinib
- Tipifarnib
- Larotrectinib
- Palbociclib
- Erdafitinib
- Vemurafenib
Breakdown of trials Alexander J. Chou has run
Cancer
Non-Hodgkin's Lymphoma
Brain Tumor
Hepatoblastoma
Langerhans Cell Histiocytosis
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Alexander J. Chou specialize in?
Alexander J. Chou focuses on Cancer and Non-Hodgkin's Lymphoma. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are FOXO1 fusion negative.
Is Alexander J. Chou currently recruiting for clinical trials?
Yes, Alexander J. Chou is currently recruiting for 2 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Alexander J. Chou has studied deeply?
Yes, Alexander J. Chou has studied treatments such as Selpercatinib, Tipifarnib, Larotrectinib.
What is the best way to schedule an appointment with Alexander J. Chou?
Apply for one of the trials that Alexander J. Chou is conducting.
What is the office address of Alexander J. Chou?
The office of Alexander J. Chou is located at: NYP/Weill Cornell Medical Center, New York, New York 10065 United States. This is the address for their practice at the NYP/Weill Cornell Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.